Topics, formats and features to give you the best possible experience
BOARD-LEVEL VIEW ON HOW TO MAKE RUSSIA COMPETITIVE IN ATTRACTING INVESTMENTS
Join top international executives and well-known leaders, who will share their views on what Russia can offer in board-level discussions on long-term revenue generation prospects. The panel will feature Patrick Aghanian, Head of Eurasia Region, Sanofi Russia, William Charnetski, Vice-President, Corporate Affairs International, AstraZeneca, Anders Tullgren, Senior Vice-President , Europe, BMS
This session, featuring representatives of top regulators, will discuss the further development of regulatory mechanisms for the pharmaceutical market, consider key reasons and necessary steps for creating a healthy competitive environment in the sector, and offer views on how to perfect and enforce price regulation policies
WHAT IS NEXT FOR THE RUSSIAN PHARMA MARKET?
Share your ideas with the most successful MDs and CEOs of the leading pharmaceutical companies working in Russia, who will come together to discuss the most important commercial and market challenges, as well as assess the healthcare system’s key pressure points
Head-to Head Discussions: 1) GENERICS VS. BRANDS - Finding the right balance between innovation and fair competition, and 2) BIOGENERIC PRODUCERS VS. BIOLOGICS INNOVATORS - Should we expect biosimilars to become a game-changer in Russia?
HEALTH CARE FUNDING: What does the future hold for reimbursement and pricing regulation?
The panel, featuring regulators, producers, insurance companies, academics and strategic consultants, will focus on the recent suggestions and models for changes in healthcare funding and reimbursement
DISTRIBUTION STRATEGY DEBATE – Models to enable collaboration and efficiency
Pharmaceutical companies are under increasing pressure to preserve their profit margins. Will manufacturers and distributors continue to rely on each other’s actions and resources to minimise distribution risks? What are the current dynamics between manufacturers, distributors and retail pharmacies, in terms of sales volumes, price setting and product assortment strategies? Looking at the key niche distributors, regional players and short-lines
GROWTH OF LOCAL PRODUCTION AND DEVELOPMENT OF LOCAL PRODUCERS
Analysing the strategies of leading national players: What are the most promising business models? With state programmes focusing on supporting local innovation and with the growing costs for development of new generics / biosimilars, what does the future hold for those manufacturers with few innovative products in their portfolio?
NAVIGATING RETAIL STRATEGIES IN A CHANGING ENVIRONMENT
The session will feature executives from federal and regional chains, as well as representatives of pharmaceutical companies. They will discuss growing entrance barriers (the entrance ticket price) and the commercial viability of working with bigger retail chains
SPOTLIGHT ON ASIA
Discovering strategies for fostering growth and establishing optimal partnership models
Building relationships between patient groups and the pharmaceutical industry